APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hematologic Malignancies Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Hematologic Malignancies Treatment Market Analysis and Forecast 2026-2032

22 December 2025191 pages

Choose your research edition.

Industry ResearchHematologic Malignancies Treatment Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Hematologic Malignancies Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Hematologic Malignancies Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hematologic Malignancies Treatment Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Hematologic Malignancies Treatment Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Hematologic Malignancies Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Hematologic Malignancies Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hematologic Malignancies Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hematologic Malignancies Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hematologic Malignancies Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Hematologic Malignancies Treatment include Bristol-Myers Squibb, Johnson & Johnson, AbbVie, Novartis, Roche, Amgen, Takeda, Pfizer and AstraZeneca, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Hematologic Malignancies Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hematologic Malignancies Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Hematologic Malignancies Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hematologic Malignancies Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hematologic Malignancies Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Hematologic Malignancies Treatment revenue, projected growth trends, production technology, application and end-user industry.

Hematologic Malignancies Treatment Segment by Company

Bristol-Myers Squibb

Johnson & Johnson

AbbVie

Novartis

Roche

Amgen

Takeda

Pfizer

AstraZeneca

Gilead Sciences

Hematologic Malignancies Treatment Segment by Type

Chemotherapy

Targeted Therapy

Immunotherapy

Hematologic Malignancies Treatment Segment by Disease

Leukemia

Lymphoma

Multiple Myeloma

Others

Hematologic Malignancies Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hematologic Malignancies Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hematologic Malignancies Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hematologic Malignancies Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Hematologic Malignancies Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Hematologic Malignancies Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hematologic Malignancies Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hematologic Malignancies Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Chemotherapy Major Player Table 3. Targeted Therapy Major Player Table 4. Immunotherapy Major Player Table 5. Global Hematologic Malignancies Treatment Market Size Growth Rate by Disease (US$ Million), 2021 VS 2025 VS 2032 Table 6. Leukemia Major Player Table 7. Lymphoma Major Player Table 8. Multiple Myeloma Major Player Table 9. Others Major Player Table 10. Hematologic Malignancies Treatment Industry Trends Table 11. Hematologic Malignancies Treatment Industry Drivers Table 12. Hematologic Malignancies Treatment Industry Opportunities and Challenges Table 13. Hematologic Malignancies Treatment Industry Restraints Table 14. Global Hematologic Malignancies Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Hematologic Malignancies Treatment Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Hematologic Malignancies Treatment Market Share by Region (2021-2026) Table 17. Global Hematologic Malignancies Treatment Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Hematologic Malignancies Treatment Market Share by Region (2027-2032) Table 19. Global Hematologic Malignancies Treatment Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Hematologic Malignancies Treatment Revenue Market Share by Players (2021-2026) Table 21. Global Hematologic Malignancies Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Hematologic Malignancies Treatment Key Players Headquarters & Area Served Table 23. Global Hematologic Malignancies Treatment Players, Product Type & Application Table 24. Global Hematologic Malignancies Treatment Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Hematologic Malignancies Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Hematologic Malignancies Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Hematologic Malignancies Treatment Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Hematologic Malignancies Treatment Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Hematologic Malignancies Treatment Revenue Market Share by Type (2021-2026) Table 31. Global Hematologic Malignancies Treatment Revenue Market Share by Type (2027-2032) Table 32. Global Hematologic Malignancies Treatment Revenue by Disease 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Hematologic Malignancies Treatment Revenue by Disease (2021-2026) & (US$ Million) Table 34. Global Hematologic Malignancies Treatment Revenue by Disease (2027-2032) & (US$ Million) Table 35. Global Hematologic Malignancies Treatment Revenue Market Share by Disease (2021-2026) Table 36. Global Hematologic Malignancies Treatment Revenue Market Share by Disease (2027-2032) Table 37. Bristol-Myers Squibb Company Information Table 38. Bristol-Myers Squibb Business Overview Table 39. Bristol-Myers Squibb Hematologic Malignancies Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Bristol-Myers Squibb Hematologic Malignancies Treatment Product Portfolio Table 41. Bristol-Myers Squibb Recent Development Table 42. Johnson & Johnson Company Information Table 43. Johnson & Johnson Business Overview Table 44. Johnson & Johnson Hematologic Malignancies Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Johnson & Johnson Hematologic Malignancies Treatment Product Portfolio Table 46. Johnson & Johnson Recent Development Table 47. AbbVie Company Information Table 48. AbbVie Business Overview Table 49. AbbVie Hematologic Malignancies Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. AbbVie Hematologic Malignancies Treatment Product Portfolio Table 51. AbbVie Recent Development Table 52. Novartis Company Information Table 53. Novartis Business Overview Table 54. Novartis Hematologic Malignancies Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Novartis Hematologic Malignancies Treatment Product Portfolio Table 56. Novartis Recent Development Table 57. Roche Company Information Table 58. Roche Business Overview Table 59. Roche Hematologic Malignancies Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Roche Hematologic Malignancies Treatment Product Portfolio Table 61. Roche Recent Development Table 62. Amgen Company Information Table 63. Amgen Business Overview Table 64. Amgen Hematologic Malignancies Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Amgen Hematologic Malignancies Treatment Product Portfolio Table 66. Amgen Recent Development Table 67. Takeda Company Information Table 68. Takeda Business Overview Table 69. Takeda Hematologic Malignancies Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Takeda Hematologic Malignancies Treatment Product Portfolio Table 71. Takeda Recent Development Table 72. Pfizer Company Information Table 73. Pfizer Business Overview Table 74. Pfizer Hematologic Malignancies Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Pfizer Hematologic Malignancies Treatment Product Portfolio Table 76. Pfizer Recent Development Table 77. AstraZeneca Company Information Table 78. AstraZeneca Business Overview Table 79. AstraZeneca Hematologic Malignancies Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. AstraZeneca Hematologic Malignancies Treatment Product Portfolio Table 81. AstraZeneca Recent Development Table 82. Gilead Sciences Company Information Table 83. Gilead Sciences Business Overview Table 84. Gilead Sciences Hematologic Malignancies Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Gilead Sciences Hematologic Malignancies Treatment Product Portfolio Table 86. Gilead Sciences Recent Development Table 87. North America Hematologic Malignancies Treatment Revenue by Type (2021-2026) & (US$ Million) Table 88. North America Hematologic Malignancies Treatment Revenue by Type (2027-2032) & (US$ Million) Table 89. North America Hematologic Malignancies Treatment Revenue by Disease (2021-2026) & (US$ Million) Table 90. North America Hematologic Malignancies Treatment Revenue by Disease (2027-2032) & (US$ Million) Table 91. North America Hematologic Malignancies Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. North America Hematologic Malignancies Treatment Revenue by Country (2021-2026) & (US$ Million) Table 93. North America Hematologic Malignancies Treatment Revenue by Country (US$ Million) & (2027-2032) Table 94. Europe Hematologic Malignancies Treatment Revenue by Type (2021-2026) & (US$ Million) Table 95. Europe Hematologic Malignancies Treatment Revenue by Type (2027-2032) & (US$ Million) Table 96. Europe Hematologic Malignancies Treatment Revenue by Disease (2021-2026) & (US$ Million) Table 97. Europe Hematologic Malignancies Treatment Revenue by Disease (2027-2032) & (US$ Million) Table 98. Europe Hematologic Malignancies Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Europe Hematologic Malignancies Treatment Revenue by Country (2021-2026) & (US$ Million) Table 100. Europe Hematologic Malignancies Treatment Revenue by Country (US$ Million) & (2027-2032) Table 101. China Hematologic Malignancies Treatment Revenue by Type (2021-2026) & (US$ Million) Table 102. China Hematologic Malignancies Treatment Revenue by Type (2027-2032) & (US$ Million) Table 103. China Hematologic Malignancies Treatment Revenue by Disease (2021-2026) & (US$ Million) Table 104. China Hematologic Malignancies Treatment Revenue by Disease (2027-2032) & (US$ Million) Table 105. Asia Hematologic Malignancies Treatment Revenue by Type (2021-2026) & (US$ Million) Table 106. Asia Hematologic Malignancies Treatment Revenue by Type (2027-2032) & (US$ Million) Table 107. Asia Hematologic Malignancies Treatment Revenue by Disease (2021-2026) & (US$ Million) Table 108. Asia Hematologic Malignancies Treatment Revenue by Disease (2027-2032) & (US$ Million) Table 109. Asia Hematologic Malignancies Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Asia Hematologic Malignancies Treatment Revenue by Region (US$ Million) & (2021-2026) Table 111. Asia Hematologic Malignancies Treatment Revenue by Region (US$ Million) & (2027-2032) Table 112. SAMEA Hematologic Malignancies Treatment Revenue by Type (2021-2026) & (US$ Million) Table 113. SAMEA Hematologic Malignancies Treatment Revenue by Type (2027-2032) & (US$ Million) Table 114. SAMEA Hematologic Malignancies Treatment Revenue by Disease (2021-2026) & (US$ Million) Table 115. SAMEA Hematologic Malignancies Treatment Revenue by Disease (2027-2032) & (US$ Million) Table 116. SAMEA Hematologic Malignancies Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. SAMEA Hematologic Malignancies Treatment Revenue by Country (2021-2026) & (US$ Million) Table 118. SAMEA Hematologic Malignancies Treatment Revenue by Country (US$ Million) & (2027-2032) Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Hematologic Malignancies Treatment Image Figure 2. Global Hematologic Malignancies Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hematologic Malignancies Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Chemotherapy Image Figure 5. Targeted Therapy Image Figure 6. Immunotherapy Image Figure 7. Global Hematologic Malignancies Treatment Market Size Growth Rate by Disease (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Hematologic Malignancies Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 9. Leukemia Image Figure 10. Lymphoma Image Figure 11. Multiple Myeloma Image Figure 12. Others Image Figure 13. Global Hematologic Malignancies Treatment Market Size (US$ Million) & (2021-2032) Figure 14. Global Hematologic Malignancies Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Hematologic Malignancies Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Hematologic Malignancies Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Hematologic Malignancies Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Hematologic Malignancies Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Hematologic Malignancies Treatment Revenue Market Share by Type (2021-2032) Figure 21. Global Hematologic Malignancies Treatment Revenue by Disease (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Hematologic Malignancies Treatment Revenue Market Share by Disease (2021 VS 2025 VS 2032) Figure 23. Global Hematologic Malignancies Treatment Revenue Market Share by Disease (2021-2032) Figure 24. North America Hematologic Malignancies Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Hematologic Malignancies Treatment Revenue Share by Type (2021-2032) Figure 26. North America Hematologic Malignancies Treatment Revenue Share by Application (2021-2032) Figure 27. North America Hematologic Malignancies Treatment Revenue Share by Country (2021-2032) Figure 28. United States Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Hematologic Malignancies Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Hematologic Malignancies Treatment Revenue Share by Type (2021-2032) Figure 33. Europe Hematologic Malignancies Treatment Revenue Share by Application (2021-2032) Figure 34. Europe Hematologic Malignancies Treatment Revenue Share by Country (2021-2032) Figure 35. Germany Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Hematologic Malignancies Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Hematologic Malignancies Treatment Revenue Share by Type (2021-2032) Figure 45. China Hematologic Malignancies Treatment Revenue Share by Application (2021-2032) Figure 46. Asia Hematologic Malignancies Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Hematologic Malignancies Treatment Revenue Share by Type (2021-2032) Figure 48. Asia Hematologic Malignancies Treatment Revenue Share by Application (2021-2032) Figure 49. Asia Hematologic Malignancies Treatment Revenue Share by Region (2021-2032) Figure 50. Japan Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Hematologic Malignancies Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Hematologic Malignancies Treatment Revenue Share by Type (2021-2032) Figure 58. SAMEA Hematologic Malignancies Treatment Revenue Share by Application (2021-2032) Figure 59. SAMEA Hematologic Malignancies Treatment Revenue Share by Country (2021-2032) Figure 60. Brazil Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Hematologic Malignancies Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
Applications
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Others
Companies covered
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • AbbVie
  • Novartis
  • Roche
  • Amgen
  • Takeda
  • Pfizer
  • AstraZeneca
  • Gilead Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hematologic Malignancies Treatment Market by Type
  3. 1.2.1 Global Hematologic Malignancies Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Chemotherapy
  5. 1.2.3 Targeted Therapy
  6. 1.2.4 Immunotherapy
  7. 1.3 Hematologic Malignancies Treatment Market by Disease
  8. 1.3.1 Global Hematologic Malignancies Treatment Market Size by Disease, 2021 VS 2025 VS 2032
  9. 1.3.2 Leukemia
  10. 1.3.3 Lymphoma
  11. 1.3.4 Multiple Myeloma
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Hematologic Malignancies Treatment Market Dynamics
  1. 2.1 Hematologic Malignancies Treatment Industry Trends
  2. 2.2 Hematologic Malignancies Treatment Industry Drivers
  3. 2.3 Hematologic Malignancies Treatment Industry Opportunities and Challenges
  4. 2.4 Hematologic Malignancies Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Hematologic Malignancies Treatment Market Perspective (2021-2032)
  2. 3.2 Global Hematologic Malignancies Treatment Growth Trends by Region
  3. 3.2.1 Global Hematologic Malignancies Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hematologic Malignancies Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Hematologic Malignancies Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Hematologic Malignancies Treatment Revenue by Players
  2. 4.1.1 Global Hematologic Malignancies Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Hematologic Malignancies Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Hematologic Malignancies Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hematologic Malignancies Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Hematologic Malignancies Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Hematologic Malignancies Treatment Players, Product Type & Application
  8. 4.5 Global Hematologic Malignancies Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Hematologic Malignancies Treatment Market CR5 and HHI
  11. 4.6.3 2025 Hematologic Malignancies Treatment Tier 1, Tier 2, and Tier 3
5 Hematologic Malignancies Treatment Market Size by Type
  1. 5.1 Global Hematologic Malignancies Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Hematologic Malignancies Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Hematologic Malignancies Treatment Revenue Market Share by Type (2021-2032)
6 Hematologic Malignancies Treatment Market Size by Application
  1. 6.1 Global Hematologic Malignancies Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Hematologic Malignancies Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Hematologic Malignancies Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bristol-Myers Squibb
  2. 7.1.1 Bristol-Myers Squibb Company Information
  3. 7.1.2 Bristol-Myers Squibb Business Overview
  4. 7.1.3 Bristol-Myers Squibb Hematologic Malignancies Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bristol-Myers Squibb Hematologic Malignancies Treatment Product Portfolio
  6. 7.1.5 Bristol-Myers Squibb Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Hematologic Malignancies Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Hematologic Malignancies Treatment Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 AbbVie
  14. 7.3.1 AbbVie Company Information
  15. 7.3.2 AbbVie Business Overview
  16. 7.3.3 AbbVie Hematologic Malignancies Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 AbbVie Hematologic Malignancies Treatment Product Portfolio
  18. 7.3.5 AbbVie Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Hematologic Malignancies Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Hematologic Malignancies Treatment Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Hematologic Malignancies Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche Hematologic Malignancies Treatment Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Amgen
  32. 7.6.1 Amgen Company Information
  33. 7.6.2 Amgen Business Overview
  34. 7.6.3 Amgen Hematologic Malignancies Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Amgen Hematologic Malignancies Treatment Product Portfolio
  36. 7.6.5 Amgen Recent Developments
  37. 7.7 Takeda
  38. 7.7.1 Takeda Company Information
  39. 7.7.2 Takeda Business Overview
  40. 7.7.3 Takeda Hematologic Malignancies Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Takeda Hematologic Malignancies Treatment Product Portfolio
  42. 7.7.5 Takeda Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Hematologic Malignancies Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Hematologic Malignancies Treatment Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 AstraZeneca
  50. 7.9.1 AstraZeneca Company Information
  51. 7.9.2 AstraZeneca Business Overview
  52. 7.9.3 AstraZeneca Hematologic Malignancies Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 AstraZeneca Hematologic Malignancies Treatment Product Portfolio
  54. 7.9.5 AstraZeneca Recent Developments
  55. 7.10 Gilead Sciences
  56. 7.10.1 Gilead Sciences Company Information
  57. 7.10.2 Gilead Sciences Business Overview
  58. 7.10.3 Gilead Sciences Hematologic Malignancies Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Gilead Sciences Hematologic Malignancies Treatment Product Portfolio
  60. 7.10.5 Gilead Sciences Recent Developments
8 North America
  1. 8.1 North America Hematologic Malignancies Treatment Revenue (2021-2032)
  2. 8.2 North America Hematologic Malignancies Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Hematologic Malignancies Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Hematologic Malignancies Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Hematologic Malignancies Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Hematologic Malignancies Treatment Revenue by Disease (2021-2032)
  7. 8.4.1 North America Hematologic Malignancies Treatment Revenue by Disease (2021-2026)
  8. 8.4.2 North America Hematologic Malignancies Treatment Revenue by Disease (2027-2032)
  9. 8.5 North America Hematologic Malignancies Treatment Revenue Share by Disease (2021-2032)
  10. 8.6 North America Hematologic Malignancies Treatment Revenue by Country
  11. 8.6.1 North America Hematologic Malignancies Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Hematologic Malignancies Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Hematologic Malignancies Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Hematologic Malignancies Treatment Revenue (2021-2032)
  2. 9.2 Europe Hematologic Malignancies Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Hematologic Malignancies Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Hematologic Malignancies Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Hematologic Malignancies Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Hematologic Malignancies Treatment Revenue by Disease (2021-2032)
  7. 9.4.1 Europe Hematologic Malignancies Treatment Revenue by Disease (2021-2026)
  8. 9.4.2 Europe Hematologic Malignancies Treatment Revenue by Disease (2027-2032)
  9. 9.5 Europe Hematologic Malignancies Treatment Revenue Share by Disease (2021-2032)
  10. 9.6 Europe Hematologic Malignancies Treatment Revenue by Country
  11. 9.6.1 Europe Hematologic Malignancies Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Hematologic Malignancies Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Hematologic Malignancies Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Hematologic Malignancies Treatment Revenue (2021-2032)
  2. 10.2 China Hematologic Malignancies Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Hematologic Malignancies Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Hematologic Malignancies Treatment Revenue by Type (2027-2032)
  5. 10.3 China Hematologic Malignancies Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Hematologic Malignancies Treatment Revenue by Disease (2021-2032)
  7. 10.4.1 China Hematologic Malignancies Treatment Revenue by Disease (2021-2026)
  8. 10.4.2 China Hematologic Malignancies Treatment Revenue by Disease (2027-2032)
  9. 10.5 China Hematologic Malignancies Treatment Revenue Share by Disease (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hematologic Malignancies Treatment Revenue (2021-2032)
  2. 11.2 Asia Hematologic Malignancies Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Hematologic Malignancies Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Hematologic Malignancies Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Hematologic Malignancies Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Hematologic Malignancies Treatment Revenue by Disease (2021-2032)
  7. 11.4.1 Asia Hematologic Malignancies Treatment Revenue by Disease (2021-2026)
  8. 11.4.2 Asia Hematologic Malignancies Treatment Revenue by Disease (2027-2032)
  9. 11.5 Asia Hematologic Malignancies Treatment Revenue Share by Disease (2021-2032)
  10. 11.6 Asia Hematologic Malignancies Treatment Revenue by Country
  11. 11.6.1 Asia Hematologic Malignancies Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Hematologic Malignancies Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Hematologic Malignancies Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hematologic Malignancies Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Hematologic Malignancies Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Hematologic Malignancies Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Hematologic Malignancies Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Hematologic Malignancies Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Hematologic Malignancies Treatment Revenue by Disease (2021-2032)
  7. 12.4.1 SAMEA Hematologic Malignancies Treatment Revenue by Disease (2021-2026)
  8. 12.4.2 SAMEA Hematologic Malignancies Treatment Revenue by Disease (2027-2032)
  9. 12.5 SAMEA Hematologic Malignancies Treatment Revenue Share by Disease (2021-2032)
  10. 12.6 SAMEA Hematologic Malignancies Treatment Revenue by Country
  11. 12.6.1 SAMEA Hematologic Malignancies Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Hematologic Malignancies Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Hematologic Malignancies Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst